Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.

Inclusion Criteria: * Male or Female age \>/= 18 years of age * Life expectancy \>/= 12 weeks * Histologically or cytologically confirmed diagnosis of HCC, unresectable advanced or metastatic * Liver function status of Child-Pugh class A. Child-Pugh status based on clinical findings and laboratory results during the screening period * Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1 * Patients must have at least one naïve (not previously treated by locoregional therapy) uni-dimensional measurable lesion by CT or MRI according to RECIST 1.1 * Adequate bone marrow, liver and renal function Exclusion Criteria: * Previous or concurrent cancer other than HCC, except for cervical carcinoma in situ, basal cell carcinoma, superficial bladder tumors. * History of cardiac disease: Congestive heart failure (CHF), unstable angina, arrhythmias, Uncontrolled hypertension * Clinically significant GI bleeding (CTCAE grade 3 or higher) within 30 days * Renal failure requiring hemo- or peritoneal dialysis * Known human immunodeficiency virus (HIV) infection * Known history or symptomatic metastatic brain or meningeal tumors * History of organ allograft. * History of interstitial lung disease (ILD). * Excluded previous therapies and medications: * Prior use of systemic anti-cancer treatment for HCC including cytotoxic chemotherapy, targeted agents, or any experimental therapy * Radiotherapy within 4 weeks prior to start of study treatment * Any other investigational agents within 4 weeks from the first dose of study treatment * Major surgery within 4 weeks of start of study * Concomitant use of strong inhibitors and strong inducers of CYP3A4